Reports Q3 revenue $1.666M, consensus $72.56k. “I am proud of the meaningful progress we have made over the last few months, most notably, the initiation of our BLA submission of cretostimogene for our lead indication of HR BCG-unresponsive NMIBC with CIS with or without Ta/T1 disease. With cretostimogene’s unique profile, we remain committed to advancing a robust clinical, regulatory, and technical strategy designed to support an optimized label and expansion into additional indications-positioning cretostimogene as a potential backbone therapy for a broad range of NMIBC patients,” said Arthur Kuan, Chairman & Chief Executive Officer at CG Oncology (CGON). “We look forward to sharing additional data from BOND-003 Cohort P and CORE-008 Cohort A before year-end.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- enGene price target raised to $10 from $4 at UBS
- Optimistic Growth Potential for CG Oncology, Inc. Driven by Positive Regulatory Precedents and Strategic Pricing
- CG Oncology’s Phase 2 Study: A New Hope for High-Risk NMIBC
- Positive Outlook for CG Oncology: Buy Rating Affirmed Amid Regulatory Progress and Operational Efficiency
- Promising Developments and Market Expansion Potential Drive Buy Rating for CG Oncology, Inc.